From September 6-9, the 41st National Pharmaceutical Industry Information Annual Conference and the 2023 China Top 100 Pharmaceutical Companies Ranking Release Ceremony were held in Chengdu. During the event, Qidu Pharma was once again listed among China's Top 100 Pharmaceutical Companies for the 11th consecutive year, with its ranking rising to 87th place. The company was also recognized as one of "China's Most Investment-Worthy Pharmaceutical Enterprises in 2024."  

With the theme "Perseverance · Innovation · A Brighter Future," the conference focused on the latest industrial policies, explored industry development trends, and promoted deep integration between the pharmaceutical industry and the full-chain innovation ecosystem. The rankings, based on national statistical data and comprehensive evaluation of corporate innovation capabilities, industrial layout, growth potential, and brand influence, represent the most authoritative and socially impactful professional selection in China's pharmaceutical industry.  Steadfast Commitment to Core Business Drives Development

Over more than two decades since its restructuring, Qidu Pharma has achieved a hundredfold growth in key economic indicators, transforming from a struggling local pharmaceutical factory into one of China's top pharmaceutical companies. This success stems from unwavering perseverance.

In Prosperity, Staying Level-Headed: Avoiding impulsive decisions and expansion, the company remains focused on its core business, striving for specialization and excellence.

In Adversity, Never Giving Up: Facing challenges—whether during the difficult early days of restructuring, land acquisition for factory construction, financial crises, or the COVID-19 pandemic—with a positive and resilient mindset, the company has treated hardships as stepping stones for growth, accumulating experience and strengthening its capabilities to achieve breakthroughs against the odds.  

In Stability, Never Slacking: Staying true to its original aspirations, enduring solitude, and continuously improving, the company emphasizes first-class management, consistently prioritizing and advancing project construction, product R&D, management innovation, corporate culture development, leadership team building, and workforce development to steadily enhance its overall strength.  

Pursuing Breakthroughs Through Innovation and Quality Enhancement

In recent years, Qidu Pharma has continuously achieved new milestones in high-quality development, thanks to its emphasis on and commitment to reform and innovation.  

Digital Transformation and Intelligent Manufacturing Leadership:

The company has pioneered the modernization of traditional industries with advanced concepts and cutting-edge technologies, launching several intelligent production projects, including:  

- An annual production capacity of 1 billion PP ampoule injections  

- An annual production capacity of 1 billion bottles/bags of new infusion solutions  

- An annual production capacity of 10 billion oral solid doses (including antibiotics, anti-tumor drugs, and hormonal preparations)  

These projects represent significant breakthroughs in production equipment and digitalization, reaching international advanced standards.  

Technology-Driven Growth:

The company has consistently pursued a dual approach of industry-academia-research collaboration and independent R&D, establishing long-term partnerships with prestigious institutions such as Peking University, Shandong University, Tianjin University, and East China University of Science and Technology. Many collaborative achievements have overcome "bottleneck" technologies, filled domestic gaps, and replaced imports. Additionally, leveraging platforms like the National Enterprise Technology Center and the Postdoctoral Research Station, the company continues to enhance its independent R&D capabilities.  

Management Innovation for Solid Foundations:

The company has implemented excellence performance management, established a "Three-Comprehensiveness and One Integration" quality management model, and created a distinctive "One Body, Two Wings, Three Supports" safety assurance system. It has also fully executed the "Three Key Projects" of management strengthening, talent-driven growth, and innovation breakthroughs, laying a solid foundation for long-term, stable, and healthy development.  

Cluster Development for a Brighter Future

Building on over two decades of solid accumulation and steady growth since its restructuring, Qidu Pharma will leverage the construction of its Health Industrial Park as an opportunity to drive new breakthroughs in project construction and R&D. The company will vigorously develop six major business segments:  

1. Drug formulations  

2. Specialty APIs  

3. Pharmaceutical packaging materials  

4. Medical consumables and devices  

5. Traditional Chinese medicine and wellness  

6. Biopharmaceuticals  

It will also foster new momentum in pharmaceutical wholesale, retail, and logistics distribution clusters, making greater contributions to building China into a pharmaceutical powerhouse and advancing the high-quality development of the pharmaceutical industry.